OBJECTIVE: To measure the level of stigma over drug taking duration among male patients with substance use disorder (including mild, moderate, severe and relapse) in Pakistan. STUDY DESIGN: Cross-sectional research design was used in this study, and data were collected through simple random sampling methods. PLACE AND DURATION OF STUDY: The research was conducted during the period of December, 2019 to December, 2020. The sample was collected from different drug treatment and rehabilitation centres located in Karachi, Islamabad, Peshawar, Quetta, Lahore and Faisalabad cities of Pakistan. SUBJECTS AND METHODS: In the current study, 508 male patients with substance use disorder (i.e. 125 mild, 125 moderate, 132 severe and 126 relapse patients with substance use disorder) were selected from different drug treatment and rehabilitation centres located in major cities of Pakistan. After taking consent, Substance Abuse Self-Stigma Scale was used to collect the data. RESULTS: The results of the current study showed that a significant difference existed at the level of stigma among mild, moderate, severe and relapse male patients with substance use disorder and the P<.05 which is .000**. The results showed that the level of stigma of substance use disorder varied on the basis of severity of use of substance, i.e., mild, moderate, severe and relapse patients with substance use disorder. >< .05 which is .000**. The results showed that the level of stigma of substance use disorder varied on the basis of severity of use of substance, i.e., mild, moderate, severe and relapse patients with substance use disorder. CONCLUSION: The stigma of the substance use has critical effects on the mental health of patients with substance use disorder. The stigma of substance use disorder is harsher than the stigma of other mental illnesses. It was observed that the level of the stigma had a variation based on the severity of substance use, and the results of the current study verified this assumption. This study will help the mental health professionals, medical and educational experts and the families of the patients with substance use disorder.